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A small series of 5-nitro-2-aminothiazole-based amides containing arylpiperazine-, biphenyl- or ary-
loxyphenyl groups in their core were synthesized and evaluated as antitrypanosomatid agents. All tested
compounds were active or moderately active against Trypanosoma cruzi amastigotes in infected L6 cells
and Trypanosoma brucei brucei, four of eleven compounds were moderately active against Leishmania
donovani axenic parasites while none were deemed active against T. brucei rhodesiense. For the most
active/moderately active compounds a moderate selectivity against each parasite was observed. There
was good correlation between lipophilicity (clogP value) and antileishmanial activity or toxicity against
L6 cells. Similarly, good correlation existed between clogP values and IC50 values against T. cruzi in
structurally related subgroups of compounds. Three compounds were more potent as antichagasic agents
than benznidazole but were not activated by the type I nitrorectusase (NTR).
© 2016 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
American trypanosomiasis (Chagas disease), human African
trypanosomiasis (HAT or sleeping sickness) and leishmaniasis are
considered neglected tropical diseases (NTD) and represent a se-
vere global health problem [1,2]. It is estimated that together these
three diseases, caused by protozoan parasitic infections, affect
approximately 20 million people and are responsible for more than
110,000 deaths annually [2]. African trypanosomiasis is endemic in. brucei, Trypanosoma brucei;
osoma cruzi; Bnz, benznida-
e); Nfx, nifurtimox (4-(5-
,1-dioxide); NTR, type I
l 14a-demethylase enzyme;
wth inhibition; SI, selectivity
ealthSystem, Department of
201, USA.
. Papadopoulou).
r Masson SAS. This is an open accemany sub-Saharan African countries and is caused by Trypanosoma
brucei rhodesiense and T. brucei gambiense. Chagas disease, caused
by Trypanosoma cruzi, is endemic in South and Central America but
is now spreading worldwide, mainly due to human and vector
migration [3,4]. Leishmaniasis, caused by more than 20 Leishmania
species, occurs throughout tropical and sub-tropical regions and is
now spreading worldwide as an HIV co-infection [5].
Treatment of these NTD is currently based on a series of prob-
lematic drugs. Thus, nifurtimox (Nfx) and benznidazole (Bnz), the
two currently used medications for Chagas disease are associated
with limited efﬁcacy, severe toxicity and long treatment re-
quirements [6,7]. Similarly, drugs used to treat HAT and leish-
maniasis are highly toxic (e.g. melarsoprol, antimonials), may
require i.v. administration (e.g. melarsoprol, suramin, DFMO, anti-
monials), can cause severe side effects, or are of high cost (e.g.
DFMO, liposomal amphotericin B, miltefosine and paromomycin)
[8e10]. Therefore, there is an urgent need for new effective, safe
and affordable alternatives.
Although inhibitors of the fungal sterol 14a-demethylasess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(TcCYP51) demonstrated promising efﬁcacy against Chagas disease
in preclinical studies [11e13], data from clinical trials using pos-
aconazole or ravuconazole were disappointing [14,15]. Moreover,
recent evidence indicates that nitroheterocyclics might be more
efﬁcacious trypanocidal agents than CYP51 inhibitors [16], and
combinations of the two may offer even a better solution [17].
We have shown that several chemical classes of 3-nitro-1H-
1,2,4-triazole-based compounds exhibit excellent antichagasic ac-
tivity both in vitro and in vivo [18e25]. Furthermore, appreciable
anti-HAT activity was also observed in vitro with several such an-
alogs [18e25] whereas in vitro antileishmanial activity was
demonstrated with a sub-class of 3-nitrotriazole- and 2-
nitroimidazole-based aryloxyphenylamides [25]. Nitro-activation
by an oxygen-insensitive type I nitroreductase (NTR), an enzyme
located in the mitochondrion of trypanosomatids and absent from
most other eukaryotes, is partially responsible for the trypanocidal
activity of these and other nitroheterocyclic compounds
[18,19,21e29]. More recently, we have synthesized 3-nitrotriazole-
based rigid amides and carbinols which act as bifunctional agents;
they exert their antitrypanosomal activity upon activation by type I
NTRs and by inhibiting the parasite's CYP51 enzyme [23,25].
Interestingly, 3-nitrotriazole-based compounds are signiﬁcantly
more potent and less toxic than their 2-nitroimidazole-based
counterparts [18e25,30].
Here we have expanded our research by investigating the role
that another nitroheterocyclic ring, 5-nitro-2-aminothiazole, plays
in antitrypanosomatid activity. Nitrothiazole- and
nitrobenzothiazole-containing compounds exhibit antiparasitic,
antibacterial, antifungal and antitubercular activities [31e34].
Therefore, we have synthesized and evaluated in vitro a small series
of 5-nitro-2-aminothiazole-based compounds bearing moieties
that were previously proven effective in the trypanocidal activity of
3-nitrotriazole-based agents.
2. Results and discussion
2.1. Chemistry
The synthesis of 5-nitro-2-aminothiazole-based compounds
(Table 1) is straightforward and based on well-established chem-
istry, outlined in Scheme 1.
The precursor alkylchloride 1 as well as compound 8 were
formed by nucleophilic substitution of 2-chloroacetyl chloride and
[1,10-biphenyl]-4-carbonyl chloride, respectively, by 5-nitro-2-
aminothiazole, in the presence of triethylamine. Amides 2e7
were obtained by nucleophilic substitution of alkylchloride 1 by an
appropriate piperazine at room temperature and in the presence of
triethylamine. Finally, amides 9e12 were prepared by nucleophilic
substitution of alkylchloride 1 by the potassium salt of an appro-
priate phenol in DMF, by heating for 3e4 h at 60 C. Efforts were
made to improve the yield of amides 9e12 by changing the solvent
to anhydrous DMSO or CH3CN without any positive results. All ﬁnal
compounds and intermediates were characterized by 1H NMR (500
or 400 MHz) and HRMS.
2.2. Biological evaluation
2.2.1. Antiparasitic activity and cytotoxicity
Compounds in Table 1 were screened for antiparasitic activity
against three trypanosomatids: T. cruzi, T. b. rhodesiense and
Leishmania donovani. The concentration of compound that inhibits
parasite growth by 50% (IC50) was calculated from dose response
curves for each parasite (Table 1). In addition, compounds were
tested for toxicity in L6 rat skeletal myoblasts, used as host cells forT. cruzi amastigotes, in order to calculate a selectivity index for each
parasite (SI¼ IC50L6/IC50parasite) (Table 1). Antiparasitic activity was
evaluated according to the following criteria: an IC50 of <4.0 mM,
between 4.0 and 60 mM or >60 mM, designates ‘active’, ‘moderately
active’ or ‘inactive’ compounds, respectively, against T. cruzi
amastigotes; for blood stream form (BSF) T. b. rhodesiense, IC50
values of <0.5 mM, between 0.5 and 6.0 mM or >6.0 mM identify
‘active’, ‘moderately active’ or ‘inactive’ compounds, respectively;
ﬁnally, for L. donovani amastigotes, IC50 of <1 mM, between 1.0 and
6.0 mMor >6.0 mM, provides ‘active’, ‘moderately active’ or ‘inactive’
compounds, respectively [35].
According to the criteria set above, all tested compounds in
Table 1 were active or moderately active antichagasic agents (green
or light green, respectively). Four compounds (6, 9, 10 and 12) were
moderately active (light green) against L. donovani parasites
whereas no compound demonstrated antiparasitic activity against
T. b. rhodesiense. Moreover, all compounds showed PSA
values > 100 Å2, which makes them highly unlikely to be capable of
penetrating the bloodebrain barrier and demonstrate anti-HAT
activity in vivo.
Several analogs (3, 5e9) demonstrated IC50 values < 50 mM
against L6 host cells, presumably due to their high lipophilicity
(Table 1), resulting in low selectivity indices. However, even com-
pounds with IC50 values > 50 mM against L6 cells demonstrated a
less than ideal SI, which is desired to be 50 for T. cruzi and20 for
L. donovani [35].
2.2.2. SAR analysis of antichagasic activity
The compounds in Table 1 were synthesized having in mind 3-
nitro-1,2,4-triazole-based analogs with known substantial trypa-
nocidal properties, described previously by this group [20,23e25].
Taking a closer look at the piperazine derivatives 2e7, we observe
that these yielded IC50 values against T. cruzi parasites ranging from
0.571 to 9.31 mM; thus they are 1.1- to 9-fold less potent than the
corresponding 3-nitrotriazole-based analogs (IC50 values
0.169e4.64 mM) [24]. Similarly, the aryl/aryloxy-derivatives 8e12
were only moderately active antichagasic agents, compared to 3-
nitrotriazole-based aryloxyphenylamides which demonstrate
T. cruzi IC50 values at low nM concentrations [23,25]. Therefore,
clearly 5-nitro-2-aminothiazole-based amides are less potent
antichagasic agents than their 3-nitrotriazole-based analogs.
Another general observation is that the 5-nitro-2-
aminothiazole-based amides are signiﬁcantly more lipophilic
(Table 1) than their 3-nitrotriazole-based counterparts with the
latter having clogP values between 0.198 and 3.1. In addition, 5-
nitro-2-aminothiazole-based amides demonstrate higher PSA
values than their 3-nitrotriazole-based analogs (the latter having
PSA values less than 116 [24]), which may negatively affect cell
permeation [36]. These features may contribute to the higher
toxicity of the nitroaminothiazoles in L6 cells and their reduced
potency against the parasites (Table 1).
Therewas an excellent correlation between antichagasic activity
and lipophilicity (R2 ¼ 0.979) in the piperazine-amide subgroup of
compounds 3e7 (which were active against T. cruzi) as shown in
Fig. 1. Thus, the piperazine amide 6 with the highest clogP value
(4.51) was the most active compound against T. cruzi, demon-
strating an IC50 of 571 nM, 3.86-fold more active than Bnz (Table 1).
Compound 6, however, was about 8-fold less active than its 3-
nitrotriazole-based analog, in which the piperazinic ring is
directly connected with the carbonyl (piperazide) and the nitro-
triazole ring is connected with the carbonyl through a methylene
group [24]. SAR follows the same rules observed in the 3-
nitrotriazole-based piperazines and piperazides [20,24]. There-
fore, dichlorophenylpiperazine 5 was a slightly better antichagasic
agent than triﬂuoromethylphenylpiperazine 3, the latter
Table 1
In vitro antiparasitic activity, host toxicity and physical properties of 5-nitro-2-amino-thiazole-based amides.
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yphenylpiperazine 4 or the heteroarylpiperazine 7. It is not clear if
the electronic effect of substitution plays a role in activity other
than inﬂuencing the clogP value.
With regard to in the structurally related compounds 8e12,there was also excellent correlation between antichagasic activity
and lipophilicity (R2 ¼ 0.977), with the most lipophilic biphenyla-
mide 8 having the lowest IC50 value against T. cruzi (Fig. 2). Inter-
estingly, and despite their relatively high lipophilicity, the
(phenoxy/phenyl)phenoxy-derivatives 9e12were only moderately
Scheme 1. Synthesis of compounds on Table 1.
Fig. 1. Correlation between antichagasic activity (log IC50 values against T. cruzi) and
lipophilicity (clogP values) in 3e7, compounds that are active against T. cruzi and bear a
piperazine moiety.
Fig. 2. Correlation between antichagasic activity (log IC50 values against T. cruzi) and
lipophilicity (clogP values) in the subgroup of structurally similar compounds 8e12.
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aryloxyphenylamides, which were exceptionally active (at low nM
concentrations) against T. cruzi [25].2.2.3. Analysis of anti-Leishmania activity
There was no correlation between antichagasic and anti-
leishmanial activity for compounds 2e12. Thus, compounds 9, 10
and 12 that displayed a moderate antichagasic activity (IC50 values
of 23e35 mM) demonstrated high potency towards L. donovani,
yielding IC50s of 4.27e5.40 mM.In contrast to antichagasic activity and, with the exception of the
most lipophilic compound 6, the 3-nitro-2-aminothiazole-based
piperazine amides 2e7 were generally less active antileishmanial
agents than the (phenoxy/phenyl)phenoxy derivatives 9e12. With
regard to the role of substitution in the antileishmanial activity, the
same rules existed, which were mentioned above for antichagasic
activity. There was good correlation between clogP and logIC50
values against L. donovani parasites for all compounds (Table 1),
regardless of activity (Fig. 3). Therefore, once again, lipophilicity
was very important determinant for antileishmanial activity.
However, lipophilicity also resulted in relatively high toxicity with
good correlation between clogP values and logIC50 values in L6 cells
(Fig. 4).
Fig. 3. Correlation between log IC50 values against L. donovani and clogP values for
compounds in Table 1.
Fig. 4. Correlation between log IC50 values in L6 cells and clogP values for compounds
in Table 1.
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To elucidate themechanism of action of the novel compounds in
Table 1, representative derivatives (3, 5, 6, 7, 8 and 11) were eval-
uated as substrates of puriﬁed, recombinant TbNTR and their
enzyme speciﬁc activity, measured as nmol NADH oxidized
min1 mg1 protein, compared with that of benznidazole (Fig. 5).
With the exception of compound 3, all other tested analogs were
deemed to be poor TbNTR substrates, consistent with results ob-
tained for previously studied N-substituted 5-nitro-2-
aminothiazoles where the substituent had electron withdrawing
groups [37]. Compound 3, which was not the most potent analogFig. 5. Speciﬁc activity values are measured in nmol NADH oxidized min1 mg1
TbNTR. The values correspond to averages from assays performed in
triplicate ± standard deviation.against T. cruzi amastigotes, provided a similar TbNTR speciﬁc ac-
tivity to BNZ (Fig. 5).
To further determine whether NTR plays a role in metabolizing
the substrates within the parasite, the above subset of compounds
were phenotypically screened against BSF T. b. brucei expressing
wild type or elevated levels of TbNTR. Compound 7, with an
IC50 > 10 mM in wild type parasites was not screened against the
recombinant line. For most of the remaining compounds cells
overexpressing TbNTR were only 2- to 3-fold more sensitivity than
controls to the agent, a relatively low shift when compared to that
observed with nifurtimox. The biochemical and phenotypic
screening data suggest that NTR plays little or no role in the
metabolism of these compounds within the parasite itself. As these
‘non-TbNTR’ activated compounds display moderate growth
inhibitory properties towards wild type T. b. brucei (Table 2) the
mode of action of these compounds remains unknown although
this antitrypanosomal activity does appear to be sub-species spe-
ciﬁc: The selected 5-nitrothiazole-based compounds tested are up
to 12-fold more potent towards T. b. brucei than against T. b.
rhodesiense.
In conclusion, novel N-substituted 5-nitro-2-aminothiazoles
with an arylpiperazine-, biphenyl- or aryloxyphenyl group in the
core were active or moderately active antichagasic agents and
moderately active against T. b. brucei parasites. Only one derivative,
compound 6, demonstrated activity against T. cruzi amastigotes at
nM concentrations and was about 4-fold more potent than BNZ. In
addition, some of these compounds demonstrated a moderate
antileishmanial activity against L. donovani axenic amastigotes.
These particular compounds were not good substrates for type I
NTR. However, more simple N-substituted 5-nitro-2-
aminothiazoles were shown to be excellent substrates of type I
NTR and their antiparasitic activity was increased about 10-fold in
NTR overexpressing T. b. brucei [37]. Interestingly, these more
simple N-acyl substituted 5-nitro-2-aminothiazoles demonstrated
signiﬁcantly lower clogP values than the compounds described in
here [37]. Therefore, this class of compounds deserves further
investigation and structural optimization may provide leads for
further development.3. Experimental
3.1. Chemistry
3.1.1. General
All starting materials and solvents were purchased from Sig-
maeAldrich (Milwaukee, WI), were of research-grade quality and
used without further puriﬁcation. Solvents used were anhydrous
and the reactions were carried out under a nitrogen atmosphere
and exclusion of moisture. Melting points were determined by
using a Mel-Temp II Laboratory Devices apparatus (Holliston, MA)
and are uncorrected. Proton NMR spectra were obtained on a
Varian Inova-500 or an Agilent Hg-400 spectrometer at 500 or
400 MHz, respectively, and are referenced to Me4Si or to the cor-
responding solvent, if the solvent was not CDCl3. High-resolution
electrospray ionization (HRESIMS) mass spectra were obtained on
a Agilent 6210 LC-TOF mass spectrometer at 11,000 resolution.
Thin-layer chromatography was carried out on aluminum oxide N/
UV254 or polygram silica gel G/UV254 coated plates (0.2 mm, Anal-
tech, Newark, DE). Chromatography was carried out on preparative
TLC alumina GF (1000 microns) or silica gel GF (1500 microns)
plates (Analtech). All ﬁnal compounds were puriﬁed by preparative
TLC chromatography on silica gel or alumina plates and also
checked by HPLC (95% purity).
Table 2
Activity of selected nitrothiazoles against wild type and TbNTR overexpressing T. b. brucei parasites in the presence of tetracycline (þtet).
Compound IC50 value (mM) T.b. brucei Ratio
Wild type TbNTR (tet) TbNTR (þtet) etet/þtet
nfx 3.980 ± 0.150 6.359 ± 0.119 0.869 ± 0.046 7.3
3 1.019 ± 0.045 1.460 ± 0.113 0.526 ± 0.024 2.8
5 1.365 ± 0.091 1.957 ± 0.101 0.747 ± 0.075 2.6
6 1.474 ± 0.104 1.638 ± 0.069 0.636 ± 0.022 2.6
7 21.575 ± 3.630 e e e
8 1.612 ± 0.396 4.587 ± 0.149 2.176 ± 0.085 2.1
11 3.753 ± 0.383 3.249 ± 0.142 2.200 ± 0.100 1.5
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[33]
A suspension of 5-nitrothiazol-2-amine (1 eq) and triethylamine
(1.1 eq) in 10 mL dichloromethane was added drop wise to a
dichloromethane solution (5e7 mL) of 2-chloroacetyl chloride (1.1
eq) and the reaction was left overnight at room temperature.
Alternatively, the solution of 2-chloroacetyl chloride was added at
once to the suspension of 5-nitrothiazol-2-amine and triethyl-
amine. The TLC on silica gel with ethyl acetate: petroleum ether
(75:25) indicated completion of the reaction. The desired product
was isolated as light yellow crystals through column chromatog-
raphy as above: 481 mg (81% yield).
3.1.3. General synthesis of N-(5-nitrothiazol-2-yl)acetamides 2e7
A dichloromethane solution (6 mL) of an appropriate piperazine
(1 eq) and triethylamine (3 eq) was added drop wise to a suspen-
sion of 2-chloro-N-(5-nitrothiazol-2-yl)acetamide (1) in 5 mL
CH2Cl2 and the reaction was kept at room temperature under a
nitrogen atmosphere and stirring for 48 h. The reaction solvent was
evaporated and the residue was redissolved in ethyl acetate. The
inorganic salts were ﬁltered away and the residue was chromato-
graphed on preparative TLC silica gel plates with ethyl acetate/pe-
troleum ether as eluent to obtain the desired pure product as a
powder or crystals. Purity was also checked by HPLC and it was
95%.
3.1.3.1. N-(5-nitrothiazol-2-yl)-2-(4-(p-tolyl)piperazin-1-yl)acet-
amide (2). Orange microcrystallic powder (62%): mp 160e161 C
(dec); 1H NMR (400 MHz, (CDCl3) d: 8.33 (s, 1H), 7.10 (d, J ¼ 7.6 Hz,
2H), 6.85 (d, J¼ 8.8 Hz, 2H), 3.38 (s, 2H), 3.23 (t, J¼ 4.8 Hz, 4H), 2.81
(t, J ¼ 5.2 Hz, 4H), 2.29 (s, 3H). HRESIMS calcd for C16H20N5O3S m/z
[MþH]þ 362.1281 found 362.1285.
3.1.3.2. N-(5-nitrothiazol-2-yl)-2-(4-(4-(triﬂuoromethyl)phenyl)
piperazin-1-yl)acetamide (3). Orange powder (55%): mp
173e175 C; 1H NMR (400 MHz, (CDCl3) d: 8.33 (s, 1H), 7.51 (d,
J ¼ 8.4 Hz, 2H), 6.96 (d, J ¼ 8.4 Hz, 2H), 3.40 (s, 2H), 3.38 (t,
J ¼ 5.2 Hz, 4H), 2.82 (t, J ¼ 5.2 Hz, 4H). HRESIMS calcd for
C16H16N8O4S m/z [MþH]þ 416.1010, found 416.1005.
3.1.3.3. 2-(4-(4-methoxyphenyl)piperazin-1-yl)-N-(5-nitrothiazol-2-
yl)acetamide (4). Bright orange powder (57%): mp 154e156 C
(dec); 1H NMR (400 MHz, (CDCl3) d: 8.33 (s, 1H), 6.91 (d, J ¼ 8.8 Hz,
2H), 6.86 (d, J ¼ 9.2 Hz, 2H), 3.78 (s, 3H), 3.39 (s, 2H), 3.17 (t,
J ¼ 4.8 Hz, 4H), 2.81 (t, J ¼ 4.8 Hz, 4H). HRESIMS calcd for
C16H20N5O4S m/z [MþH]þ 378.1231 found 378.1233.
3.1.3.4. 2-(4-(3,4-dichlorophenyl)piperazin-1-yl)-N-(5-nitrothiazol-
2-yl)acetamide (5). Bright yellow microcrystals (65%): mp
169e171 C; 1H NMR (400 MHz, (CD3COCD3) d: 8.44 (s, 1H), 7.36 (d,
J ¼ 9.2 Hz, 1H), 7.12 (d, J ¼ 2.8 Hz, 1H), 6.97 (dd, J ¼ 9.2, 2.8 Hz, 1H),
3.53 (s, 2H), 3.37 (t, J¼ 5.2 Hz, 4H), 2.84 (t, J¼ 5.2 Hz, 4H). HRESIMScalcd for C15H16Cl2N5O3S m/z [MþH]þ 416.0345, 418.0317, found
416.0346, 418.0317.
3.1.3.5. 2-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)-N-(5-
nitrothiazol-2-yl)acetamide (6). Orange microcrystallic powder
(66%): mp 92e95 C; 1H NMR (400 MHz, (CDCl3) d: 8.31 (s, 1H),
7.36e7.21 (m, 9H), 4.27 (s, 1H), 3.31 (s, 2H), 2.66 (t, J ¼ 4.8 Hz, 4H),
2.49 (br s, 4H). HRESIMS calcd for C22H23ClN5O3S m/z [MþH]þ
472.1205, found 472.1209.
3.1.3.6. N-(5-nitrothiazol-2-yl)-2-(4-(pyridin-2-yl)piperazin-1-yl)
acetamide (7). Orange microcrystallic powder (56%): mp
175e180 C (dec); 1H NMR (400 MHz, (CDCl3) d: 8.33 (s, 1H), 8.21
(dd, J ¼ 4.4, 1.2 Hz, 1H), 7.52 (dt, J ¼ 8.4, 2.0 Hz, 1H), 6.68 (m, 2H),
3.65 (t, J¼ 4.8 Hz, 4H) 3.38 (s, 2H), 2.76 (t, J¼ 4.8, Hz, 4H). HRESIMS
calcd for C14H17N6O3S m/z [MþH]þ 349.1077 found 349.1083.
3.1.4. N-(5-nitrothiazol-2-yl)-[1,10-biphenyl]-4-carboxamide (8)
[1,10-Biphenyl]-4-carbonyl chloride was added in portions to a
suspension of 5-nitrothiazol-2-amine (1 eq) and triethylamine (2.5
eq) in 10e12 mL dichloromethane. The reaction mixture was kept
at room temperature overnight under stirring and a nitrogen at-
mosphere. The desired product was obtained after preparative TLC
on silica gel plates using ethyl acetate: petroleum ether (50:50) as
eluent. Beige microcrystals (55%): mp > 230 C; 1H NMR (400 MHz,
(CD3COCD3) d: 8.50 (s, 1H), 8.31 (d, J ¼ 8.8 Hz, 2H), 7.92 (d,
J¼ 8.8 Hz, 2H), 7.78 (d, J¼ 7.6 Hz, 2H), 7.53 (t, J¼ 7.6 Hz, 2H), 7.45 (t,
J ¼ 7.6 Hz, 1H). HRESIMS calcd for C16H10N3O3S m/z [MH]
324.0448 found 324.0464.
3.1.5. General synthesis of N-(5-nitrothiazol-2-yl)acetamides 9e12
An appropriate phenol (1.05 eq) and K2CO3 (2.1 eq) were mixed
together in dry DMF (4 mL) and stirred for an hour. Then a DMF
solution (4 mL) of 2-chloro-N-(5-nitrothiazol-2-yl)acetamide (1 eq)
was added through a funnel and the reactionmixturewas heated at
60 C for 3e4 h. The solvent was evaporated and the residue was
chromatographed on silica gel preparative TLC plates using ethyl
acetate: petroleum ether mixture as an eluent. The desired product
is formed in relatively small yield (35%) and appears immediately
after the unreacted phenol on TLC. Changing the solvent to CH3CN
or DMSO did not improve the yield.
3.1.5.1. 2-([1,10-biphenyl]-3-yloxy)-N-(5-nitrothiazol-2-yl)acetamide
(9). White microcrystals (25%): mp 148e150 C; 1H NMR
(400 MHz, (CClD3) d: 9.94 (br s, 1H), 8.36 (s, 1H), 7.60e7.33 (m, 7H),
7.21 (dd, J ¼ 2.4, 1.6 Hz, 1H), 6.96 (dd, J ¼ 7.2, 2.4, Hz, 1H), 4.85 (s,
2H). HRESIMS calcd for C17H14N3O4S m/z [MþH]þ 356.0700, found
356.0696.
3.1.5.2. N-(5-nitrothiazol-2-yl)-2-(3-phenoxyphenoxy)acetamide
(10). White microcrystals (34%, based on recovered phenol): mp
151e153 C; 1H NMR (400 MHz, (CDCl3) d: 9.84 (br s, 1H), 8.35 (s,
M.V. Papadopoulou et al. / European Journal of Medicinal Chemistry 117 (2016) 179e186 1851H), 7.38 (t, J ¼ 7.6 Hz, 2H), 7.30 (t, J ¼ 8.0 Hz, 1H), 7.17 (t, J ¼ 8.0 Hz,
1H), 7.05 (d, J ¼ 7.6 Hz, 2H), 6.73 (dd, J ¼ 8.0, 2.0 Hz, 1H), 6.68 (dd,
J ¼ 8.0, 2.4 Hz, 1H), 6.62 (t, J ¼ 2.4 Hz, 1H), 4.74 (s, 2H). HRESIMS
calcd for C17H14N3O5S m/z [MþH]þ 372.0648, found 372.0649.
3.1.5.3. 2-([1,10-biphenyl]-4-yloxy)-N-(5-nitrothiazol-2-yl)acetamide
(11). Light yellow microcrystals (35%, based on recovered phenol):
mp 196e198 C; 1H NMR (400 MHz, CDCl3) d: 8.36 (s, 1H), 7.60 (d,
J ¼ 8.8 Hz, 2H), 7.55 (dd, J ¼ 8.0, 0.8 Hz, 2H), 7.44 (t, J ¼ 7.2 Hz, 2H),
7.35 (t, J ¼ 7.6 Hz, 1H), 7.06 (d, J ¼ 8.8 Hz, 2H), 4.83 (s, 2H). HRESIMS
calcd for C17H14N3O4S m/z [MþH]þ 356.070, found 356.0694.
3.1.5.4. N-(5-nitrothiazol-2-yl)-2-(4-phenoxyphenoxy)acetamide
(12). Off white microcrystals (30%): mp 185e187 C; 1H NMR
(400 MHz, (CDCl3) d: 9.91 (br s, 1H), 8.36 (s, 1H), 7.33 (t, J ¼ 8.0 Hz,
2H), 7.10 (t, J¼ 7.6 Hz,1H), 7.05e6.95 (m, 6H), 4.77 (s, 2H). HRESIMS
calcd for C17H14N3O5S m/z [MþH]þ 372.0649, found 372.0655.
3.2. Biological evaluation
3.2.1. In vitro screening
In vitro activity against T. cruzi, T. b. rhodesiense, L. donovani and
cytotoxicity assessment using L6 cells (rat skeletal myoblasts) was
determined using a 96-well plate format as previously described
[38]. Data were analyzed with the graphic program Softmax Pro
(Molecular Devices, Sunnyvale, CA, USA), which calculated IC50
values by linear regression from the sigmoidal dose inhibition
curves.
3.2.2. In vitro T. brucei brucei antiproliferating assays and
susceptibility studies
T. brucei brucei bloodstream form parasites were seeded at
1  103 mL1 in 200 mL of growth medium containing different
concentrations of a nitrothiazole or nifurtimox. Where appropriate,
induction of the TbNTR was carried out by adding tetracycline
(1 mg/mL). After incubation for 3 days at 37 C, resazurin (2.5 mg per
well) was added to each well and the plates incubated for a further
8 h. The cell density of each culture was determined as described
before [26] and the IC50 established.
3.2.3. Enzymatic activity studies with type I NTRs
Recombinant TbNTR was prepared and assayed as previously
described [39,40]. The activity of puriﬁed his-tagged TbNTR was
assessed spectrophotometrically at 340 nm using various nitro-
thiazole substrates (100 mM) and NADH (100 mM) with the enzyme
speciﬁc activity expressed as nmol NADH oxidized min1 mg1 of
enzyme. Benznidazole was used as control substrate.
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